Within a susceptible wild-type population, a small fraction of cells, even< 10− 9, is not
affected when challenged by an antimicrobial agent. This subpopulation has mutations that …

Pharmacokinetic/pharmacodynamic (PK/PD) analysis has proved to be very useful to
establish rational dosage regimens of antimicrobial agents in human and veterinary …

Understanding the evolution of microorganisms under antibiotic treatments is a burning
issue. Typically, several resistance mutations can accumulate under antibiotic treatment …

The story of antituberculosis chemotherapy is a miniature of the history of anti-infective
chemotherapy. In the first half of the 20th century the problem of tuberculosis appeared …

The mutant selection window is an antimicrobial concentration range extending from the
minimal concentration required to block the growth of wild-type bacteria up to that required …

Large-scale, systems biology approaches now allow us to systematically map synergistic
and antagonistic interactions between drugs. Consequently, drug antagonism is emerging …

Although the fluoroquinolones are presently used to treat tuberculosis primarily in cases
involving resistance or intolerance to first-line antituberculosis therapy, these drugs are …

The mutant selection window hypothesis postulates that, for each antimicrobial-pathogen
combination, an antimicrobial concentration range exists in which selective amplification of …

Studies with fluoroquinolones have led to a general method for restricting the selection of
antibiotic-resistant mutants. The strategy is based on the use of antibiotic concentrations that …

Rifampin is a cornerstone of modern antituberculosis therapy. However, rifampin's half-life of
3 h is believed to limit its utility for intermittent therapy, so new congeners with long half-lives …